ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.Journal of Korean medical science · 2020Pooled it
- Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Critical reviews in oncology/hematology · 2013Pooled it
- The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.Journal of bone and mineral metabolism · 2021Trial
- Incidence of frailty-related fracture among Medicaid beneficiaries living with HIV and cancer: A cohort study.PloS one · 2026Article
- Knowledge, attitudes, and practices regarding osteoporosis among hormone receptor-positive breast cancer patients: a cross-sectional study.Frontiers in public health · 2026Article
- Incidence of frailty-related fracture among Medicaid beneficiaries living with HIV and cancer: A cohort study.medRxiv : the preprint server for health sciences · 2025Article
- Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study.Breast cancer research : BCR · 2025Article
- Keep calm and keep rowing: the psychophysical effects of dragon boat program in breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women.Journal of cancer research and clinical oncology · 2024Article
- Article
- Fracture Risk Among Older Cancer Survivors Compared With Older Adults Without a History of Cancer.JAMA oncology · 2023Article
- Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.Current treatment options in oncology · 2021Review
- From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.Current oncology (Toronto, Ont.) · 2021Article
- Article
- Hip fractures in the elderly without osteoporosis.Journal of frailty, sarcopenia and falls · 2018Article
- Physical activity and annual medical outlay in U.S. colorectal, breast and prostate cancer survivors.Preventive medicine reports · 2018Article
- Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.Journal of bone oncology · 2017Review
- Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.British journal of cancer · 2016Article
- Elevated incidence of fractures in women with invasive breast cancer.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- Cancer Treatment-Induced Bone Loss in women with breast cancer.BoneKEy reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
purposeAromatase inhibitors (AIs) have been recently associated with hip fractures. We present a case series of breast cancer survivors and a systematic review of bone health care in breast cancer. EXPERIMENTAL
designWe completed clinical assessments and bone density testing (BMD) of hip fractures from January 2005 to December 2008. Prefracture and 12-month functional status was obtained. Systematic review included case reports and review of MEDLINE, PubMed, EMBASE, and Food and Drug Administration Adverse Event Reporting System (FDA AERS) from January 1998 to December 2008 (search terms: breast cancer, bone loss, osteopenia, osteoporosis, malignancy, cancer treatment, menopause, adriamycin, cytoxan, tamoxifen, and AIs).
resultsMedian age was 53.5 years; five women had osteopenia, one osteoporosis. Five cases were ER (+), and received surgery, XRT chemotherapy, and anastrozole. Functional decline was noted at 12 months, with difficulty in performing heavy housekeeping, climbing stairs, and shopping. The FDA AERS database included 228 cases of fractures associated with breast cancer therapy; 77/228 (29.4%) were hip or femur fractures. Among mid-life women under the age of 64 years there were 78 fractures; 15/228 (19%) were hip and femur fractures. AIs were the most common drug class associated with fractures (n = 149, 65%).
conclusionsCancer treatment induced bone loss results in hip fractures among mid-life women with breast cancer. Hip fractures occur at younger ages and higher BMD than expected for patients in this age group without breast cancer. Hip fractures result in considerable functional decline. Greater awareness of this adverse drug effect is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.